[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpesvirus-4-human\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpesvirus-4-human":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100551692","deep-learning-based-sborn-diagnostic-model-100551692",false,"NCT06463392","Deep Learning-based sbORN Diagnostic Model","Development of Deep-Learning-Based Multimodal Post Radiotherapy Skull-Base Osteonecrosis and Recurrence of Nasopharyngeal Carcinoma Differential Diagnostic Model","Inclusion Criteria:\n\n* Equal to or older than 18 years old.\n* A history of histologically confirmed nonkeratinizing undifferentiated nasopharyngeal carcinoma.\n* A history of radical radiotherapy at nasopharynx.\n* Complete remission six months post radical radiotherapy according to RECIST 1.1.\n* No evidence of distant metastasis upon recruitment.\n* Diagnosis of sbORN given by senior radiologist with 2-4 Likert scores.\n* Consent to biopsy awake or under general anesthesia.\n* Consent to perform blood tests, EBV DNA, EBV IgAs, and MRI inspection of nasopharynx and neck.\n* With a written consent.\n\nExclusion Criteria:\n\n* MRI artifacts or other factors that interfere radiological diagnosis and region of interest contouring.\n* Suspected lesion is not confined to nasopharynx and skull-base.","ALL","18 Years",{"count":19,"type":20},312,"ESTIMATED","OBSERVATIONAL","Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.",[24,25],"Nasopharyngeal Carcinoma","Herpesvirus 4, Human",[24,27,28,29],"Skull-base Osteonecrosis","Radiotherapy","Epstein-Barr Virus","RECRUITING","2024-09-27",{"date":33,"type":34},"2024-10-01","ACTUAL",{"date":36,"type":34},"2024-07-01",{"date":38,"type":20},"2030-12-31",{"name":40,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":42},"100540830","sequencing-based-counting-of-plasma-epstein-barr-virus-dna-in-non-metastatic-nasopharyngeal-carcinoma-100540830","NCT06321939","Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Newly diagnosed, pathologically proven World Health Organization (WHO) type II\u002FIII untreated NPC;\n2. Non-metastatic NPC (I-IVA, according to the 8th edition of the AJCC\u002FUICC clinical staging system);\n3. Age at diagnosis: over 18 years old;\n4. Eastern Cooperative Oncology Group (ECOG) score: 0-1\n5. Receiving recommended curative intention treatments：definitive radiotherapy w\u002Fwo three cycles of induction chemotherapy (IC) (gemcitabine-cisplatin \\[GP\\] or paclitaxel-cisplatin \\[TP\\] regimen);\n6. Pre-treatment and post-IC1 cell-free Epstein-Barr virus (cfEBV) DNA \\> 0 copy\u002FmL; systemic cfEBV DNA monitoring during IC phase for risk stratification;\n7. Normal hematic, liver, and kidney function: hemoglobin (HG) \\> 90 g\u002FL; neutrophil \\> 1.5 × 109\u002FL; platelet \\> 100 × 109\u002FL; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN; alkaline phosphatase (ALP) ≤ 2.5 × ULN; creatinine clearance (Ccr) ≥ 60 mL\u002Fmin;\n8. Female subjects capable of becoming pregnant agree to use reliable contraceptive measures from screening to 1 year after treatment;\n9. Patients will be required to sign informed consent forms and be willing and able to comply with the requirements for visits, treatment, laboratory tests, and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Receiving surgery, target therapy, and\u002For immunotherapy during or before induction phase;\n2. Other previous or concurrent malignant tumors, except adequately treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary cancer;\n3. Pregnant or lactating women (a pregnancy test should be considered for fertile women with an active sex life);\n4. Previously treated with radical radiotherapy (RT), except non-melanoma skin cancers outside intended RT treatment volume;\n5. Uncontrolled heart disease, e.g.: 1) Heart failure, New York Heart Association (NYHA) level ≥ 2; 2) unstable angina; 3) myocardial infarction in the past 1 year; 4) supraventricular or ventricular arrhythmia requiring treatment or intervention.",{"count":50,"type":20},50,"The investigators aim to explore a new EBV DNA surveillance method with both high sensitivity and specificity in nasopharyngeal carcinoma (NPC) patients. the investigators aim to conduct plasma EBV DNA counting by next generation sequencing (NGS) in non-metastatic NPC patients on their diagnose, after two cycles of induction chemotherapy (IC), and 4-8 weeks after definitive radiotherapy. The investigators aim to explore whether sequencing-based counting is better than PCR analysis in plasma EBV-DNA surveillance, so as to monitoring tumor responses to treatment and for guiding individualized treatment adaptation in the future.",[24,25],"2024-03-14",{"date":55,"type":34},"2024-03-20",{"date":57,"type":34},"2024-01-11",{"date":59,"type":20},"2028-12-31",{"name":61,"class":41},"Hunan Cancer Hospital"]